apoA-I (CSL112) / CSL Behring - LARVOL DELTA

The challenges in improving myocardial infarction outcomes and the year 2024 in a nutshell. (PubMed, Future Cardiol) - No abstract available

Journal • Cardiovascular • Myocardial Infarction

Advancing Secondary Prevention Post-Myocardial Infarction With CSL112. (PubMed, JACC Basic Transl Sci) - No abstract available

Journal • Cardiovascular • Myocardial Infarction

Apolipoprotein A1 (CSL112) Increases Lecithin-Cholesterol Acyltransferase Levels in HDL Particles and Promotes Reverse Cholesterol Transport. (PubMed, JACC Basic Transl Sci) - "CSL112 reduced levels of apolipoproteins A2, B, C, and E and serum amyloids A1 and A4, whereas ApoA1, ApoM, and lecithin-cholesterol acyltransferase were significantly elevated. Increased CEC, plasma HDL cholesterol levels, CER, and CEC also were observed in CSL112-treated patients."

Journal • Cardiovascular • Myocardial Infarction • APOA1

Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol Levels. (PubMed, JACC Adv) - P3 | "Baseline elevated NLR predicts MACE in post-AMI patients, and CSL112 showed an associated reduction in MACE in patients with elevated NLR and LDL-C ≥100 mg/dL."

Journal • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Inflammation • Myocardial Infarction • APOA1

APOLIPOPROTEIN A-I INFUSIONS AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION AND MODERATE RENAL IMPAIRMENT: INSIGHTS FROM THE AEGIS-II TRIAL - Gerald Chi (ACC 2025) - P3 | "In the subgroup of patients with moderate renal impairment, treatment with CSL112 was associated with a significant reduction in the risk of CV death, MI, or stroke at 180 and 365 days compared to placebo."

Clinical • Cardiovascular • Chronic Kidney Disease • Coronary Artery Disease • Myocardial Infarction • Nephrology • Renal Disease • APOA1

APOLIPOPROTEIN A-I INFUSIONS AND CARDIOVASCULAR OUTCOMES IN ACUTE MYOCARDIAL INFARCTION ACCORDING TO NEUTROPHIL-LYMPHOCYTE RATIO AND BASELINE LDL-CHOLESTEROL LEVELS: INSIGHTS FROM THE AEGIS-II TRIAL - Sem Rikken (ACC 2025) - P3 | "Higher NLR was associated with a higher risk of MACE. CSL112 may reduce MACE in participants with both higher NLR and LDL-C ≥100 mg/dL."

Cardiovascular • Myocardial Infarction • APOA1

Quo Vadis after AEGIS: New Opportunities for Therapies Targeted at Reverse Cholesterol Transport? (PubMed, Curr Atheroscler Rep) - "However, the AEGIS-II trial of CSL112, an apolipoprotein A-I therapy that enhances cholesterol efflux, did not meet its primary endpoint...The role of HDL therapeutics in patients with familial hypercholesterolaemia, inherited low HDL-cholesterol and impaired HDL function, especially with inadequately controlled LDL-cholesterol, merits further investigation. The treatment of patients with monogenic defects in HDL metabolism remains a significant gap in care that needs further research."

Journal • Review • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Familial Hypercholesterolemia • APOA1

Apolipoprotein A1 infusion in patients with Acute Myocardial Infarction: A Systematic Review and Meta-analysis of randomized trials (AHA 2024) - "Our findings suggest that the administration of CSL112 was not associated with a reduction in mortality, SAE or MACE in patients with acute myocardial infarction."

Retrospective data • Review • Cardiovascular • Myocardial Infarction • APOA1

The impact of CSL112 and atorvastatin on lipid core stiffness in murine atherosclerotic plaques (AHA 2024) - "Statistical analysis indicated that CSL112 significantly increased the elastic modulus of lipid cores compared to both atorvastatin and saline (p <0.001), while lipid stiffness was also significantly higher in the atorvastatin group compared to saline (p = 0.039).Conclusion. The increase in lipid pool stiffness within atherosclerotic plaques treated with CSL112 and atorvastatin may reduce the level of PSS and enhance plaque structural stability."

Preclinical • Atherosclerosis • Dyslipidemia • APOA1 • APOE

Infusion of human apolipoprotein A-I (CSL112) promotes several aspects of reverse cholesterol transport (AHA 2024) - "CSL112 altered HDL composition and increased HDL functionality by promoting multiple steps of the reverse cholesterol transport pathway."

Cardiovascular • Myocardial Infarction • APOA1 • SAA1

ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights From the AEGIS-II Trial. (PubMed, J Am Coll Cardiol) - P3 | "In this prespecified exploratory analysis of the AEGIS-II trial, 4 weekly infusions of CSL112 among high-risk patients after AMI significantly reduced the total burden of nonfatal ischemic events and CV death at 180 and 365 days compared with placebo. (AEGIS-II [Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome]; NCT03473223)."

Journal • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Myocardial Infarction • APOA1

Apolipoprotein A-I Infusions and Cardiovascular Outcomes in Acute Myocardial Infarction According to Baseline LDL-Cholesterol Levels: The AEGIS-II Trial. (PubMed, Eur Heart J) - P3 | "In this population, treatment with CSL112 compared to placebo was associated with a significantly lower risk of recurrent cardiovascular events among patients with a baseline LDL-C ≥100 mg/dL. Further studies need to confirm that CSL112 efficacy is influenced by baseline LDL-C."

Journal • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Myocardial Infarction • APOA1

New perspectives on the high-density lipoprotein system and its role in the prevention and treatment of atherosclerotic cardiovascular disease. (PubMed, Curr Opin Endocrinol Diabetes Obes) - "Qualitative markers of HDL may be causally related to CVD. There is a need for ongoing research into HDL therapeutics that promote the biological properties of HDL. The optimal cohort or disease state that will benefit from these therapies needs to be identified."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • APOA1

CSL112 and HDL function hypothesis - a never-ending wait. (PubMed, Expert Rev Clin Pharmacol) - No abstract available

Journal • Cardiovascular • Myocardial Infarction

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference. (PubMed, Curr Atheroscler Rep) - "The LIBerate-HR trial showed the efficacy and safety of lerodalcibep, a subcutaneous injection that prevents binding of Pro-Protein Convertase Subtilisin/Kexin (PCSK) 9 to low-density lipoprotein (LDL)-receptors resulting in LDL-cholesterol (LDL-C) lowering in patients at very high risk or high risk of atherosclerotic CV disease (ASCVD). The AEGIS-II randomized patients with type 1 myocardial infarction (MI) with multivessel coronary artery disease and additional CV risk factors and found no benefit in major adverse CV events (MACE) with CSL112, an apolipoprotein A1 infusion shown to increase cholesterol efflux capacity. The Bridge-TIMI 73a trial showed a significant reduction in triglyceride (TG) levels with olezarsen, an antisense mRNA, in patients with moderate hyperTG with elevated CV risk...The VICTORIAN-INITIATE trial showed efficacy and safety in early use of inclisiran in patients with ASCVD who did not reach target LDL-C < 70 mg/dL despite maximally..."

Journal • Review • Atherosclerosis • Cardiomyopathy • Cardiovascular • Coronary Artery Disease • Diabetes • Dyslipidemia • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus • AKR1B1 • APOA1

Enhancing HDL Function to Prevent Atherothrombosis: Is it Time to Efflux the HDL Hypothesis? (PubMed, J Am Coll Cardiol) - No abstract available

Journal • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Myocardial Infarction • Thrombosis

Can CSL-112 Revolutionize Atherosclerosis Treatment? A Critical Look at the Evidence. (PubMed, Curr Probl Cardiol) - "Larger, well-designed trials with longer follow-up periods are necessary to definitively establish its clinical benefit and safety profile before widespread clinical use can be considered. Future research should also explore deeper into the pharmacokinetic and pharmacodynamic profile of CSL-112 and explore its efficacy and safety in different patient subgroups."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Immunology • Myocardial Infarction • APOA1

CSL112 (Apolipoprotein A-I [Human]) Reduces the Elevation in Neutrophil-to-Lymphocyte Ratio Induced by Acute Myocardial Infarction. (PubMed, J Am Heart Assoc) - No abstract available

Journal • Cardiovascular • Inflammation • Myocardial Infarction • APOA1

Effect of CSL112 on Recurrent Myocardial Infarction and Cardiovascular Death: Insights from the AEGIS-II Trial. (PubMed, J Am Coll Cardiol) - "While CSL112 did not significantly reduce the occurrence of the primary study endpoints, patients treated with CSL112 infusions had numerically lower rates of CV death and MI, type-1 MI, and stent thrombosis-related MI compared to placebo. These findings could suggest a role of apoA-I in reducing subsequent plaque disruption events via enhanced cholesterol efflux. Further prospective data would be needed to confirm these observations."

Clinical • Journal • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Myocardial Infarction • Thrombosis

CSL112 (Apolipoprotein A-I) Infusions And Cardiovascular Outcomes In Patients With Acute Myocardial Infarction (ApoA-I Event Reducing In Ischemic Syndromes II (AEGIS-II) Trial): Primary Trial Results (ACC 2024) - "There is no abstract associated with this presentation."

Clinical • Late-breaking abstract • Cardiovascular • Myocardial Infarction • APOA1

CSL112 (Apolipoprotein A-I) Infusions And Cardiovascular Outcomes In Patients With Acute Myocardial Infarction (ApoA-I Event Reducing In Ischemic Syndromes II (AEGIS-II) Trial): Primary Trial Results (ACC 2024) - "Abstract is embargoed at this time."

Clinical • Late-breaking abstract • Cardiovascular • Myocardial Infarction • APOA1

HAPTOGLOBIN COPY NUMBER VARIANTS DO NOT DIMINISH THE EFFECT OF CSL112 (APOA-I [HUMAN]) ON HDL FUNCTION (ACC 2024) - "The elevation in CEC induced by CSL112 was not modified by Hp CNV status including in patients with diabetes. The capacity of CSL112 to markedly enhance CEC irrespective of Hp CNV genotype is in contrast to other therapies and supports application across a broad post-AMI population."

Atherosclerosis • Cardiovascular • Diabetes • Dyslipidemia • Metabolic Disorders • Myocardial Infarction • ABCA1 • APOA1 • HP • PON1

In perspective: CSL112 (Apolipoprotein A-I) Infusions and Cardiovascular Outcomes in Patients with Acute Myocardial Infarction: the ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II) trial. (PubMed, Eur Heart J Acute Cardiovasc Care) - No abstract available

Journal • Cardiovascular • Myocardial Infarction • APOA1

Elevation in neutrophil-to-lymphocyte ratio induced by acute myocardial infarction is reduced by CSL112 (apolipoprotein A-I [human]) (AMCP 2024) - No abstract available

Cardiovascular • Myocardial Infarction • APOA1

Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction. (PubMed, N Engl J Med) - P3 | "Among patients with acute myocardial infarction, multivessel coronary artery disease, and additional cardiovascular risk factors, four weekly infusions of CSL112 did not result in a lower risk of myocardial infarction, stroke, or death from cardiovascular causes than placebo through 90 days. (Funded by CSL Behring; AEGIS-II ClinicalTrials.gov number, NCT03473223.)."

Journal • Cardiovascular • Coronary Artery Disease • Immunology • Myocardial Infarction • APOA1